Table 3.

 Changes in haemoglobin A levels (%) between baseline and one year by subgroup of patients with non-insulin treated type 2 diabetes. Values are means (standard deviations)

Variable	Control group* (n=152)	Meter group, less intensive self monitoring (n=150)	Meter group, more intensive self monitoring (n=151)	P value for interaction†
Duration of diabetes‡
≤36 months:				0.82
Baseline	7.29 (1.02)	7.35 (1.02)	7.41 (1.03)
Follow-up	7.30 (1.24)	7.23 (0.93)	7.25 (1.01)
Change	0.01 (1.03)	−0.12 (0.85)	−0.16 (0.73)
>36 months:
Baseline	7.70 (1.13)	7.48 (1.02)	7.67 (1.20)
Follow-up	7.70 (1.11)	7.33 (0.84)	7.49 (1.08)
Change	−0.01 (1.01)	−0.15 (0.80)	−0.18 (0.73)
Baseline therapy
Diet only:				0.90
Baseline	7.18 (0.98)	6.85 (0.66)	7.18 (1.11)
Follow-up	7.21 (1.05)	6.90 (0.70)	7.09 (0.94)
Change	0.03 (0.80)	0.04 (0.64)	−0.09 (0.72)
Oral drug therapy:
Baseline	7.61 (1.11)	7.61 (1.05)	7.66 (1.10)
Follow-up	7.61 (1.24)	7.41 (0.91)	7.46 (1.07)
Change	−0.01 (1.10)	−0.20 (0.87)	−0.20 (0.73)
Health status (EQ-5D)§:
Diabetes >36 months:				0.63
Baseline	7.38 (1.02)	7.30 (0.96)	7.57 (1.21)
Follow-up	7.46 (1.16)	7.22 (0.76)	7.43 (1.16)
Change	0.07 (0.99)	−0.08 (0.84)	−0.13 (0.77)
Diabetes ≤36 months:
Baseline	7.54 (1.16)	7.50 (1.09)	7.34 (0.80)
Follow-up	7.43 (1.22)	7.37 (1.04)	7.14 (0.78)
Change	−0.11 (1.14)	−0.13 (0.80)	−0.20 (0.67)
Diabetes related complications
Absent:				0.86
Baseline	7.53 (1.11)	7.51 (1.09)	7.71 (1.19)
Follow-up	7.48 (1.16)	7.32 (0.92)	7.43 (1.13)
Change	−0.05 (1.02)	−0.19 (0.88)	−0.28 (0.74)
Present:
Baseline	7.32 (1.02)	7.07 (0.63)	7.00 (0.64)
Follow-up	7.52 (1.34)	7.12 (0.73)	7.16 (0.73)
Change	0.20 (1.02)	0.05 (0.56)	0.16 (0.56)

*No use of blood glucose meter.

†After adjustment for baseline values.

‡Median 36 months.

§EQ-5D score 0.814. Paired data for EQ-5D score available for 384 patients.